SCHEMBL31332908

SCHEMBL31332908

CCOC(=O)c1[nH]nnc1Cl

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
PDE4D Q08499 1/20 0.43
ALDH1A1 P00352 6/20 0.42
KDM4E B2RXH2 3/20 0.42
HPGD P15428 2/20 0.42
HTT P42858 1/20 0.42
RECQL P46063 1/20 0.42
ALPL P05186 1/20 0.42
HSD17B10 Q99714 1/20 0.40
CDC25B P30305 1/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
CASP1 P29466 1/20 0.38
POLB P06746 1/20 0.38
ALOX15 P16050 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9272935 0.81 PDE4D (0.50) CYP1A2CYP2C9CYP2C19PDE4DALDH1A1
SCHEMBL5648877 0.80 KDM4E (0.46) CYP1A2CYP2C9CYP2C19PDE4DALDH1A1
SCHEMBL3958675 0.79 KDM4C (0.43) CYP1A2ALDH1A1KDM4EHPGDALPL
SCHEMBL22815646 0.79 CYP1A2 (0.44) CYP1A2CYP2C9CYP2C19PDE4DALDH1A1
SCHEMBL26922505 0.77 KDM4E (0.55) CYP1A2CYP2C9CYP2C19PDE4DALDH1A1
SCHEMBL1928112 0.76 PDE4D (0.44) CYP1A2PDE4DALDH1A1KDM4EHTT
SCHEMBL19780726 0.75 KDM4E (0.43) CYP1A2CYP2C9CYP2C19PDE4DALDH1A1
SCHEMBL23294640 0.75 ALPL (0.55) ALDH1A1KDM4EALPLCDC25BKMT2A
SCHEMBL5648880 0.74 KDM4E (0.47) CYP1A2CYP2C9CYP2C19PDE4DALDH1A1
SCHEMBL23484645 0.73 CYP1A2 (0.40) CYP1A2CYP2C9CYP2C19PDE4DALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709374-A2 KCC2 POTENTIATORS AND USES THEREOF Axonis Therapeutics, Inc. (US) 2026-03-18 EP disclosed
US-20260062402-A1 KCC2 POTENTIATORS AND USES THEREOF AXONIS THERAPEUTICS INC (US) 2026-03-05 US disclosed
WO-2024233885-A2 KCC2 POTENTIATORS AND USES THEREOF AXONIS THERAPEUTICS, INC. (US) 2024-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062402-A1 KCC2 POTENTIATORS AND USES THEREOF HCN2, HCN1, HCN4 CYP1A2 1523/4885CYP2C9 813/4885CYP2C19 1384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.